{"id":8940,"date":"2025-12-08T23:02:21","date_gmt":"2025-12-08T23:02:21","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/12\/08\/terns-leukemia-drug-ash-results-tern-701\/"},"modified":"2025-12-08T23:02:21","modified_gmt":"2025-12-08T23:02:21","slug":"terns-leukemia-drug-ash-results-tern-701","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/12\/08\/terns-leukemia-drug-ash-results-tern-701\/","title":{"rendered":"STAT+: Results in Terns leukemia drug study suggest it could be a successor to Novartis blockbuster"},"content":{"rendered":"<p>    STAT+: Results in Terns leukemia drug study suggest it could be a successor to Novartis blockbuster<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>ORLANDO, Fla. \u2014 Terns Pharmaceuticals reported an update Monday on its targeted leukemia drug that maintained and even boosted molecular response rates in advanced-stage patients.\u00a0<\/p>\n<p>The study results, while still early, are likely to draw even more positive attention from investors who already view the Terns drug as a potential successor to a commercial blockbuster from Novartis.\u00a0<\/p>\n<p>At 24 weeks, four escalating doses of the Terns drug, called TERN-701, achieved a major molecular response of 64% in patients with chronic myeloid leukemia, a slow-growing cancer that starts in myeloid cells. The 28 patients evaluable had already experienced treatment with a median of three drugs.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/12\/08\/terns-leukemia-drug-ash-results-tern-701\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/12\/08\/terns-leukemia-drug-ash-results-tern-701\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Results in Terns leukemia drug study suggest it could be a successor to Novartis blockbuster ORLANDO, Fla. \u2014 Terns Pharmaceuticals reported an update Monday on its targeted leukemia drug that maintained and even boosted molecular response rates in advanced-stage patients.\u00a0 The study results, while still early, are likely to draw even more positive attention [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4374,2194,2154,2152],"tags":[2150],"class_list":["post-8940","post","type-post","status-publish","format-standard","hentry","category-ash","category-biotech","category-biotechnology","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8940"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=8940"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8940\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=8940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=8940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=8940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}